Investor Presentaiton

US Business US Business: Q2FY23 Sales of 6,040 million (YoY decline of 0.9%) • US sales contributed 19.8% to total sales in Q2FY23 • During the quarter, the US business registered sequential growth of 8.5% over Q1FY23 In Q2FY23, the Company filed 3 ANDAS with the US FDA and received 4 approvals (including 2 tentative approvals) As on September 30, 2022, the Company filed a total of 167 ANDAs and 2 new drug applications (NDA) with the US FDA and has received approvals for 128 ANDAs (including 15 tentative approvals) and 2 NDAs. Q2FY23 US Sales (mn) 6,097 YoY: (0.9%) 6,040 H1FY23 US Sales (mn) 12,140 YoY: (4.4%) 11,605 Q2FY22 Q2FY23 H1FY22 H1FY23 ALKEM

View entire presentation